Air New Zealand/Announcement
Air New Zealand logo

Disclosure of Director and Senior Mngrs Relevant Interests

Insider/Shareholder Notice21 December 2018AIRIndustrials

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of listed issuer: Air New Zealand

Date this disclosure made:21-Dec-18

Date of last disclosure: 29-Nov-18

Director or senior manager giving disclosure

Full name(s):Christopher Luxon

Name of listed issuer:Air New Zealand

Name of related body corporate (if applicable):

Position held in listed issuer:CEO

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:

Restricted Rights convertible

to Ordinary Shares

("Restricted Rights")

Nature of the affected relevant interest(s):

Power to acquire Ordinary

Shares in accordance with

terms of the Restricted Rights

For that relevant interest-

Number held in class before acquisition or disposal:753,451

Number held in class after acquisition or disposal:372,815

Current registered holder(s):Christopher Luxon

Registered holder(s) once transfers are registered:Christopher Luxon

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products: Ordinary Shares (NZX:AIR)

Nature of the affected relevant interest(s):

Registered holder:

beneficial owner

For that relevant interest-

Number held in class before acquisition or disposal:3,000,000

Number held in class after acquisition or disposal:3,380,636

Current registered holder(s):Christopher Luxon

Registered holder(s) once transfers are registered:Christopher Luxon

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

1

Details of transactions requiring disclosure

Date of transaction:

20-Dec-18

Nature of transaction:

Exercise of Rights to acquire

Ordinary Shares upon

satisfaction of terms

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition

or disposal. If the consideration was not in cash and cannot be readily by converted into a

cash value, describe the consideration:

380,636 Rights were

exercised to acquire shares,

on a one-for-one basis, at no

cost

Number of financial products to which the transaction related:

380,636

If the issuer has a financial products trading policy that prohibits directors or senior

managers from trading during any period without written clearance (a closed period)

include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to

proceed during the closed period:Not applicable

Date of the prior written clearance (if any):Not applicable

Summary of other relevant interests after acquisition or disposal
Class of affected quoted financial products:

Rights convertible to Ordinary

Shares ("Rights")

Nature of the affected relevant interest(s):

Power to acquire Ordinary

Shares in accordance with

the terms of the Rights

For that relevant interest-

Number held in class:2,006,004

Current registered holder(s):Christopher Luxon

Certification

I certify that, to the best of my knowledge and belief, the information contained in this

disclosure is correct and that I am duly authorised to make this disclosure by all persons

for whom it is made.

Signature of person authorised to sign on behalf of director or officer:

Date of signature:21-Dec-18

Name and title of authorised person:

Felicity Cammock

HR Manager Employee

Benefits

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.